Allogeneic UCB-derived CAR-T

CAR-T cell therapy (umbilical cord blood-derived) · Chengdu Ucello Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allogeneic UCB-derived CAR-T, covering 2025-12-10 to 2025-12-10. Get the full timeline:

Most recent: Clinical Trial Update: Allogeneic UCB-derived CAR-T for SLE [EARLY_Phase 1]